Erratum to: J Neurol DOI 10.1007/s00415-016-8064-9
Unfortunately, the online published article has errors in Fig. 1 (% in Fig. 1d 2/5 is 40 % and not 28 %). The original article has been corrected.
The correct Fig. 1 is given in the following page.
Changes of neurological function during Tafamidis treatment. a Change from baseline of NIS over 18 months of treatment in early (stage 1, N = 21) and late (stage 2 & 3, N = 13) stages of the disease. b Progression of neurological impairment in patients followed up over 36 months of treatment (note that patients with longer follow up had more severe disease due to inclusion of patients in stage 2–3 in the early phases of the study). c Six-month change of NIS over 18 months of treatment (N = 35). d Percentage of responders (change of NIS from baseline NIS-LL <2 points) over 36 months of treatment. NIS-LL neuropathy impairment score, NIS-LL NIS-lower limb, F-U follow-up
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00415-016-8064-9.
Rights and permissions
About this article
Cite this article
Cortese, A., Vita, G., Luigetti, M. et al. Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263, 925–926 (2016). https://doi.org/10.1007/s00415-016-8116-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8116-1